Baird Medical Investment Holdings vs Nephros
Baird Medical Investment Holdings is the larger business, with $22.5m of revenue in fiscal 2025 against $18.8m for Nephros (1.2 times as much). Nephros grew faster (32.7% against -39.2%). Nephros kept more of each dollar of sales as profit: a net margin of 6.4% against -121.0%. Nephros carries less debt relative to equity (0.0% against 27.8%).
| Latest fiscal year | Baird Medical Investment HoldingsBDMD, 2025 | NephrosNEPH, 2025 |
|---|---|---|
| Revenue | $22.5m | $18.8m |
| Revenue growth | -39.2% | 32.7% |
| Net income | −$27.3m | $1.2m |
| Operating margin | -113.7% | 6.1% |
| Net margin | -121.0% | 6.4% |
| Return on equity | -76.8% | 12.7% |
| Free cash flow | −$1.4m | $1.6m |
| Cash | $178,321 | $5.4m |
| Total debt | $8.7m | $0 |
| Debt to equity | 27.8% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $3.3m | $35.1m |
| Price vs our value range | — | — |
| Moat score | — | 31 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |